Analysis for mechanism of FGL1 expression to overcome anti-PD1 therapy resistance urological cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K18152
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: Toshio Takagi 東京女子医科大学, 医学部, 教授 (00385387)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 泌尿器がん / 腎がん / 免疫チェックポイント阻害剤 / FGL1 / LAG3

Outline of Final Research Achievements

In the treatment of metastatic renal cell carcinoma with immune checkpoint inhibitors, the analysis revealed a correlation between serum FGL1 levels and treatment efficacy and prognosis, particularly demonstrating a correlation between serum FGL1 levels at 2-3 weeks post-treatment and prognosis. Furthermore, the expression of LAG3 on tumor-infiltrating T cells was detected using flow cytometry, and its correlation with clinicopathological findings was analyzed. While the expression of LAG3 on CD4-positive T cells did not correlate with clinicopathological findings, a significant increase in LAG3 expression on CD8-positive T cells was observed in elderly, advanced-stage, and high-grade cases.

Free Research Field

泌尿器がん

Academic Significance and Societal Importance of the Research Achievements

この研究の社会的意義は、腎細胞がん治療におけるFGL1とLAG3の重要性を明らかにすることで今後の個別化されたがん治療に向けた情報として重要な点にある。免疫チェックポイント分子による免疫抑制メカニズムや臨床所見との相関性を明らかにすることで、将来的には免疫チェックポイント阻害剤治療の効果を最大化し、患者の生活の質を向上させる治療戦略を開発する基盤を提供することが期待される。